TOR-centric view on insulin resistance and diabetic complications: Perspective for endocrinologists and gerontologists

Cell Death and Disease

Volumn 4, Issue 12, 2013, Pages

  Blagosklonny, M V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

aging; diseases; rapalogs; rapamycin; senescence

Indexed keywords

INSULIN; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

CALORIC RESTRICTION; CELL AGING; CELLS; COMPLICATION; ENDOCRINOLOGIST; GERONTOLOGIST; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RETINOPATHY; REVIEW;

AGING; ANIMALS; DIABETES COMPLICATIONS; ENDOCRINOLOGY; GERIATRICS; HUMANS; INSULIN RESISTANCE; TOR SERINE-THREONINE KINASES;

EID: 84891785508     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.506     Document Type: Review

References (175)

1. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 2006; 116: 1756-1760
2. Girach A, Vignati L. Diabetic microvascular complications-can the presence of one predict the development of another. J Diabetes Complications 2006; 20: 228-237
3. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819
4. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: Implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34: 145-150
5. Ellis JD, Zvandasara T, Leese G, McAlpine R, Macewen CJ, Baines PS et al. Clues to duration of undiagnosed disease from retinopathy and maculopathy at diagnosis in type 2 diabetes: A cross-sectional study. Br J Ophthalmol 2011; 95: 1229-1233
6. Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 1998; 21: 72-80
7. Singleton JR, Smith AG. Therapy insight: Neurological complications of prediabetes. Nat Clin Pract Neurol 2006; 2: 276-282
8. Singleton JR, Smith AG. Neuropathy associated with prediabetes: What is new in 2007? Curr Diab Rep 2007; 7: 420-424
9. Meigs JB, D'Agostino RBS, Nathan DM, Rifai N, Wilson PW. Longitudinal association of glycemia and microalbuminuria: The Framingham Offspring Study. Diabetes Care 2002; 25: 977-983
10. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005; 1: 100-110
11. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24: 137-144
12. Wong TY, Mohamed Q, Klein R, Couper DJ. Do retinopathy signs in non-diabetic individuals predict the subsequent risk of diabetes? Br J Ophthalmol 2006; 90: 301-303
13. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-2873
14. Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 2002; 11: 119-123
15. Moskalets E, Galstyan G, Starostina E, Antsiferov M, Chantelau E. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J Diabetes Complications 1994; 8: 45-50
16. Chantelau E, Meyer-Schwickerath R, Klabe K. Downregulation of serum IGF-1 for treatment of early worsening of diabetic retinopathy: A long-Term follow-up of two cases. Ophthalmologica 2010; 224: 243-246
17. Agardh CD, Eckert B, Agardh E. Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control. J Diabetes Complications 1992; 6: 96-100
18. Henricsson M, Berntorp K, Berntorp E, Fernlund P, Sundkvist G. Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables. Diabetes Care 1999; 22: 1944-1949
19. Henricsson M, Janzon L, Groop L. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM. Diabetes Care 1995; 18: 1571-1576
20. Funatsu H, Yamashita H, Ohashi Y, Ishigaki T. Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn J Ophthalmol 1992; 36: 356-367
21. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: A reversible painful autonomic neuropathy. Ann Neurol 2010; 67: 534-541
22. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 2001; 276: 38052-38060
23. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: Protein synthesis or autophagy? Aging (Albany NY) 2009; 1: 586-597
24. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013; 23: 53-62
25. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35
26. Blagosklonny MV, Hall MN. Growth and aging: A common molecular mechanism. Aging 2009; 1: 357-362
27. Leontieva OV, Geraldine M, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) 2012; 4: 899-891
28. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7: 3355-3361
29. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107: 9660-9664
30. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 2012; 109: 13314-13318
31. Dulic V. Be quiet and yoúll keep young: Does mTOR underlie p53 action in protecting against senescence by favoring quiescence? Aging (Albany NY) 2011; 3: 3-4
32. Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2: 535-537
33. Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11: 4642-4649
34. Leontieva OV, Demidenk ZN, Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Deth Diff 2013; 20: 1241-1249
35. Hinojosa CA, Mgbemena V, Van Roekel S, Austad SN, Miller RA, Bose S et al. Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. Exp Gerontol 2012; 47: 958-965
36. Halicka HD, Zhao H, Li J, Lee YS, Hsieh TC, Wu JM et al. Potential anti-Aging agents suppress the level of constitutive mTOR-And DNA damage-signaling. Aging (Albany NY) 2012; 4: 952-965
37. Iglesias-Bartolome R, Gutkind SJ. Exploiting the mTOR paradox for disease prevention. Oncotarget 2012; 3: 1061-1063
38. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194-1217
39. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 2013; 123: 966-972
40. CoppŽ JP, Patil CK, Rodier F, Sun Y, Mu-oz DP, Goldstein J et al. Senescenceassociated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-2868
41. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: Terminology for TOR-driven aging. Aging (Albany NY) 2012; 4: 159-165
42. Cahu J, Bustany S, Sola B. Senescence-Associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 2012; 3: E446
43. Tominaga-Yamanaka K, Abdelmohsen K, Martindale JL, Yang X, Taub DD, Gorospe M. NF90 coordinately represses the senescence-Associated secretory phenotype. Aging (Albany NY) 2012; 4: 695-708
44. Blagosklonny MV. Answering the ultimate question 'what is the proximal cause of aging?'. Aging (Albany NY) 2012; 4: 861-877
45. Blagosklonny MV. Why men age faster but reproduce longer than women: MTOR and evolutionary perspectives. Aging (Albany NY) 2010; 2: 265-273
46. Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. Am J Pathol 2012; 181: 1142-1146
47. Blagosklonny MV. How to save Medicare: The anti-Aging remedy. Aging (Albany NY) 2012; 4: 547-552
48. Blagosklonny MV. Aging and immortality: Quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5: 2087-2102
49. Blagosklonny MV. An anti-Aging drug today: From senescence-promoting genes to antiaging pill. Drug Disc Today 2007; 12: 218-224
50. Tsang CK, Qi H, Liu LF, Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Disc Today 2007; 12: 112-124
51. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-345
52. Nair S, Ren J. Autophagy and cardiovascular aging: Lesson learned from rapamycin. Cell Cycle 2012; 11: 2092-2099
53. Williamson DL. Normalizing a hyperactive mTOR initiates muscle growth during obesity. Aging (Albany NY) 2011; 3: 83-84
54. Blagosklonny MV. Rapamycin extends life-And health span because it slows aging. Aging (Albany NY) 2013; 5: 592-598
55. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009; 460: 392-396
56. Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 2011; 3: 189-191
57. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010; 176: 2092-2097
58. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10: 4230-4236
59. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/-mice by delaying carcinogenesis. Aging (Albany NY) 2012; 4: 715-722
60. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) 2012; 4: 709-714
61. Levine AJ, Harris CR, Puzio-Kuter AM. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson disease pathway. Oncotarget 2012; 3: 1301-1307
62. Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging (Albany NY) 2012; 4: 660-661
63. Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and noncognitive components of behavior throughout lifespan in mice. Neuroscience 2012; 223: 102-113
64. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE et al. Rapamycin slows aging in mice. Aging Cell 2012; 11: 675-682
65. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ et al. Late life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 2013; 12: 851-862
66. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL et al. With TOR, less is more: A key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11: 453-465
67. Khanna A, Kapahi P. Rapamycin: Killing two birds with one stone. Aging (Albany NY) 2011; 3: 1043-1044
68. Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY) 2011; 3: 1039-1040
69. Ye L, Widlund AL, Sims CA, Lamming DW, Guan Y, Davis JG et al. Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance. Aging (Albany NY) 2013; 5: 539-550
70. Kolosova NG, Vitovtov AO, Muraleva NA, Akulov AE, Stefanova NA, Blagosklonny MV. Rapamycin suppresses brain aging in senescence-Accelerated OXYS rats. Aging (Albany NY) 2013; 5: 474-484
71. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM et al. Regulation of insulin signalling by hyperinsulinaemia: Role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 2005; 48: 506-518
72. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-1656
73. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006; 26: 63-76
74. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: Possible involvement in obesity-linked insulin resistance. Endocrinology 2005; 146: 1473-1481
75. Tremblay F, BržlŽ S, Hee UmS, Li Y, Masuda K, Roden M et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient-And obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007; 104: 14056-14061
76. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005; 54: 2674-2684
77. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB. Insulin resistance due to nutrient excess: Is it a consequence of AMPK downregulatioñ Cell Cycle 2011; 10: 3447-3451
78. Barbour LA, McCurdy CE, Hernandez TL, Friedman JE. Chronically increased S6K1 is associated with impaired IRS1 signaling in skeletal muscle of GDM women with impaired glucose tolerance postpartum. J Clin Endocrinol Metab 2011; 96: 1431-1441
79. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011; 332: 1317-1322
80. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332: 1322-1326
81. Korsheninnikova E, van der Zon GC, Voshol PJ, Janssen GM, Havekes LM, Grefhorst A et al. Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice. Diabetologia 2006; 49: 3049-3057
82. Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P et al. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007; 56: 1600-1607
83. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001; 98: 4640-4645
84. Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: Disturbed interplay between autophagy and inflammasomes. Aging (Albany NY) 2012; 4: 166-175
85. Cai D, Liu T. Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB. Aging (Albany NY) 2012; 4: 98-115
86. Blagosklonny MV. Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010; 9: 683-688
87. Glynn EL, Lujan HL, Kramer VJ, Drummond MJ, DiCarlo SE, Rasmussen BB. A chronic increase in physical activity inhibits fed-state mTOR/S6K1 signaling and reduces IRS-1 serine phosphorylation in rat skeletal muscle. Appl Physiol Nutr Metab 2008; 33: 93-101
88. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 2002; 109: 805-815
89. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
90. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613
91. Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 2006; 206: 749-758
92. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol 2004; 165: 457-469
93. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975-27981
94. Slomiany MG, Rosenzweig SA. IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest Ophthalmol Vis Sci 2004; 45: 2838-2847
95. Demidenko ZN, Blagosklonny MV. The purpose of the HIF-1/PHD feedback loop: To limit mTOR-induced HIF-1alpha. Cell Cycle 2011; 10: 1557-1562
96. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-1395
97. Lu M, Amano S, Miyamoto K, Garland R, Keough K, Qin W et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci 1999; 40: 3281-3286
98. Chantelau E, Frystyk J. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration-A case report. Growth Horm IGF Res 2005; 15: 130-135
99. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8: 1888-1895
100. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004; 10: 964-972
101. Kolosova NG, Muraleva NA, Zhdankina AA, Stefanova NA, Fursova AZ, Blagosklonny MV. Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol 2012; 181: 472-477
102. Zheng XF. Chemoprevention of age-related macular regeneration (AMD) with rapamycin. Aging (Albany NY) 2012; 4: 375-376
103. Krishnadev N, Forooghian F, Cukras C, Wong W, Saligan L, Chew EY et al. Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1627-1633
104. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404
105. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006; 340: 296-301
106. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27: 495-502
107. Rhodes CJ. Type 2 diabetes-A matter of beta-cell life and death? Science 2005; 307: 380-384
108. Mooijaart SP, van Heemst D, Noordam R, Rozing MP, Wijsman CA, de Craen AJ et al. Polymorphisms associated with type 2 diabetes in familial longevity: The Leiden Longevity Study. Aging (Albany NY) 2011; 3: 55-62
109. Newman AB, Glynn NW, Taylor CA, Sebastiani P, Perls TT, Mayeux R et al. Health and function of participants in the Long Life Family Study: A comparison with other cohorts. Aging (Albany NY) 2011; 3: 63-76
110. Leibowitz G, Bachar E, Shaked M, Sinai A, Ketzinel-Gilad M, Cerasi E et al. Glucose regulation of beta-cell stress in type 2 diabetes. Diabetes Obes Metab 12(Suppl 2): 66-75
111. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW et al. Growth hormone receptor deficiency is associated with a major reduction in pro-Aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3: 70ra13
112. Gunasekaran U, Gannon M. Type 2 diabetes and the aging pancreatic beta cell. Aging (Albany NY) 2011; 3: 565-575
113. Tacutu R, Budovsky A, Yanai H, Fraifeld VE. Molecular links between cellular senescence, longevity and age-related diseases-A systems biology perspective. Aging (Albany NY) 2011; 3: 1178-1191
114. Shigeyama Y, Kobayashi T, Kido Y, Hashimoto N, Asahara S, Matsuda T et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 2008; 28: 2971-2979
115. Leontieva OV, Paszkiewicz G, Demidenko ZN, Blagosklonny MV. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis 2013; 4: E472
116. Chen J, Huang XF. Mechanism for the synergistic effect of rapamycin and resveratrol on hyperinsulinemia may involve the activation of protein kinase B. Cell Death Dis 2013; 4: E680
117. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 2005; 280: 2282-2293
118. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283: E413-E422
119. Bachar E, Ariav Y, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS One 2009; 4: E4954
120. Allagnat F, Cunha D, Moore F, Vanderwinden JM, Eizirik DL, Cardozo AK. Mcl-1 downregulation by pro-inflammatory cytokines and palmitate is an early event contributing to beta-cell apoptosis. Cell Death Differ 2011; 18: 328-337
121. Allagnat F, Fukaya M, Nogueira TC, Delaroche D, Welsh N, Marselli L et al. C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in beta-cells. Cell Death Differ 2012; 19: 1836-1846
122. Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A, Shu YY et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl) 2011; 90: 575-585
123. Velazquez-Garcia S, Valle S, Rosa TC, Takane KK, Demirci C, Alvarez-Perez JC et al. Activation of protein kinase C-zeta in pancreatic beta-cells in vivo improves glucose tolerance and induces beta-cell expansion via mTOR activation. Diabetes 2011; 60: 2546-2559
124. Elghazi L, Balcazar N, Blandino-Rosano M, Cras-Meneur C, Fatrai S, Gould AP et al. Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in beta-cells. Diabetes 2010; 59: 2390-2399
125. Blagosklonny MV. Rapamycin-induced glucose intolerance: Hunger or starvation diabetes. Cell Cycle 2011; 10: 4217-4224
126. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: Despite of or owing to. Aging (Albany NY) 2012; 4: 350-358
127. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: Implications for the management of diabetes. Diabetologia 1985; 28: 119-121
128. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyperglycemiainduced insulin resistance in whole body and skeletal muscle of type I diabetic patients. Diabetes 1992; 41: 571-580
129. Yki-Jarvinen H. Acute and chronic effects of hyperglycaemia on glucose metabolism: Implications for the development of new therapies. Diabet Med 1997; 14(Suppl 3): S32-S37
130. Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Feres F, Staico R et al. Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: A serial intravascular ultrasound study. Catheter Cardiovasc Interv 2005; 66: 535-540
131. Rodriguez AE, Alemparte MR, Vigo CF, Pereira CF, Llaurado C, Russo M et al. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol 2003; 15: 581-584
132. Guarda E, Marchant E, Fajuri A, Martinez A, Moran S, Mendez M et al. Oral rapamycin to prevent human coronary stent restenosis: A pilot study. Am Heart J 2004; 148: E9
133. Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: Revitalizing answers to NCI's provocative questions. Oncotarget 2012; 3: 1711-1724
134. Blagosklonny MV. NCI's provocative questions on cancer: Some answers to ignite discussion. Oncotarget 2011; 2: 1352-1367
135. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: Chemoprevention with rapamycin, an mTOR inhibitor and anti-Aging drug. Am J Pathol 2012; 181: 278-293
136. Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: Phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) 2011; 3: 1078-1091
137. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3: 148-157
138. Berstein LM. Metformin in obesity, cancer and aging: Addressing controversies. Aging (Albany NY) 2012; 4: 320-329
139. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J et al. Metformin: Multi-faceted protection against cancer. Oncotarget 2011; 2: 896-917
140. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer 2010; 17: 941-951
141. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011; 2: E199
142. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis 2012; 3: E275
143. Liu Y, Huang Y, Wang Z, Li X, Louie A, Wei G et al. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY) 2013; 5: 111-119
144. Menendez JA, Cufi S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: Less is more. Aging (Albany NY) 2011; 3: 348-362
145. Moiseeva O, Deschenes-Simard X, Pollak M, Ferbeyre G. Metformin, aging and cancer. Aging (Albany NY) 2013; 5: 330-331
146. Lewis DA, Travers JB, Machado C, Somani AK, Spandau DF. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging (Albany NY) 2011; 3: 407-416
147. Floc'h N, Abate-Shen C. The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer. Oncotarget 2012; 3: 1483-1484
148. Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011; 2: 1314-1321
149. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S et al. PIK3CA mutations in advanced cancers: Characteristics and outcomes. Oncotarget 2012; 3: 1566-1575
150. Blagosklonny MV. Molecular damage in cancer: An argument for mTOR-driven aging. Aging (Albany NY) 2011; 3: 1130-1141
151. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: Conundrum or rapalog-like gerosuppressioñ Aging (Albany NY) 2012; 4: 450-455
152. Blagosklonny MV. Rapalogs in cancer prevention: Anti-Aging or anticancer? Cancer Biol Ther 2012; 13: 1349-1354
153. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-1646
154. He G, Sung YM, Digiovanni J, Fischer SM. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 2006; 66: 1873-1878
155. Fang Y, Bartke A. Prolonged rapamycin treatment led to beneficial metabolic switch. Aging (Albany NY) 2013; 5: 328-329
156. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165: 2325-2340
157. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010; 59: 1338-1348
158. Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A, Shu YY et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl) 2012; 90: 575-585
159. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM et al. Long-Term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin Pharmacol Toxicol 2009; 105: 188-198
160. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-1643
161. Lamming DW, Ye L, Astle CM, Baur JA, Sabatini DM, Harrison DE. Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. Aging Cell 2013; 12: 712-718
162. Blagosklonny MV. Linking calorie restriction to longevity through sirtuins and autophagy: Any role for TOR. Cell Death Dis 2010; 1: E12
163. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846
164. Mordier S, Iynedjian PB. Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. Biochem Biophys Res Commun 2007; 362: 206-211
165. Chan JY, Cole E, Hanna AK. Diabetic nephropathy and proliferative retinopathy with normal glucose tolerance. Diabetes Care 1985; 8: 385-390
166. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M et al. Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024
167. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698-1702
168. Ozaki KS, Camara NO, Nogueira E, Pereira MG, Granato C, Melaragno C et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21: 675-680
169. Araki K, Ellebedy AH, Ahmed R. TOR in the immune system. Curr Opin Cell Biol 2011; 23: 707-715
170. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360: 195-197
171. Bourcier ME, Sherrod A, DiGuardo M, Vinik AI. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 2009; 94: 3157-3162
172. Soliman AR, Ismail E, Zamil S, Lotfy A. Sirolimus therapy for patients with adult polycystic kidney disease: A pilot study. Transplant Proc 2009; 41: 3639-3641
173. Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study. Arthritis Rheum 2009; 60: 3821-3830
174. Gems DH, de la Guardia YI. Alternative perspectives on aging in C. elegans: Reactive oxygen species or hyperfunctioñ Antioxid Redox Signal 2013; 19: 321-329
175. Gems D, Partridge L. Genetics of longevity in model organisms: Debates and paradigm shifts. Annu Rev Physiol 2013; 75: 621-644